Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope

Journal of Molecular Biology

Volumn 428, Issue 14, 2016, Pages 2860-2879

  Yamniuk, Aaron P ^a   Suri, Anish ^a   Krystek, Stanley R ^a   Tamura, James ^a   Ramamurthy, Vidhyashankar ^a   Kuhn, Robert ^a   Carroll, Karen ^a   Fleener, Catherine ^a   Ryseck, Rolf ^a   Cheng, Lin ^a   An, Yongmi ^a   Drew, Philip ^b   Grant, Steven ^b   Suchard, Suzanne J ^a   Nadler, Steven G ^a   Bryson, James W ^a   Sheriff, Steven ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Domantis   (United Kingdom)

Author keywords

autoimmune disease; CD40; domain antibody; therapeutic; X ray structure

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CROSS REACTION; DENDRITIC CELL; EPITOPE MAPPING; HUMAN; HUMAN CELL; MACACA FASCICULARIS; MIXED LYMPHOCYTE REACTION; MOLECULAR MODEL; MUTAGENESIS; MUTANT; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENCE; TONSILLECTOMY; X RAY CRYSTALLOGRAPHY; ANIMAL; IMMUNOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, CD40; AUTOIMMUNE DISEASES; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HUMANS; MACACA FASCICULARIS;

EID: 84977275336     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.05.014     Document Type: Article

References (63)

1. [1] Quezada, S.A., Jarvinen, L.Z., Lind, E.F., Noelle, R.J., CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22 (2004), 307–328.
2. [2] Noelle, R.J., Mackey, M., Foy, T., Buhlmann, J., Burns, C., CD40 and its ligand in autoimmunity. Ann. N. Y. Acad. Sci. 815 (1997), 384–391.
3. [3] Roy, M., Waldschmidt, T., Aruffo, A., Ledbetter, J.A., Noelle, R.J., The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4 + T cells. J. Immunol. 151 (1993), 2497–2510.
4. [4] Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72 (1993), 291–300.
5. [5] DiSanto, J.P., Bonnefoy, J.Y., Gauchat, J.F., Fischer, A., de Saint Basile, G., CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 361 (1993), 541–543.
6. [6] Korthauer, U., Graf, D., Mages, H.W., Briere, F., Padayachee, M., Malcolm, S., et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 361 (1993), 539–541.
7. [7] Banatvala, N., Davies, J., Kanariou, M., Strobel, S., Levinsky, R., Morgan, G., Hypogammaglobulinaemia associated with normal or increased IgM (the hyper IgM syndrome): a case series review. Arch. Dis. Child. 71 (1994), 150–152.
8. [8] Notarangelo, L.D., Duse, M., Ugazio, A.G., Immunodeficiency with hyper-IgM (HIM). Immunodefic. Rev. 3 (1992), 101–121.
9. [9] Durie, F.H., Aruffo, A., Ledbetter, J., Crassi, K.M., Green, W.R., Fast, L.D., et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J. Clin. Invest. 94 (1994), 1333–1338.
10. [10] Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A., Noelle, R.J., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261 (1993), 1328–1330.
11. [11] Durie, F.H., Foy, T.M., Masters, S.R., Laman, J.D., Noelle, R.J., The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15 (1994), 406–411.
12. [12] Foy, T.M., Aruffo, A., Bajorath, J., Buhlmann, J.E., Noelle, R.J., Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 14 (1996), 591–617.
13. [13] Foy, T.M., Page, D.M., Waldschmidt, T.J., Schoneveld, A., Laman, J.D., Masters, S.R., et al. An essential role for gp39, the ligand for CD40, in thymic selection. J. Exp. Med. 182 (1995), 1377–1388.
14. [14] Foy, T.M., Shepherd, D.M., Durie, F.H., Aruffo, A., Ledbetter, J.A., Noelle, R.J., In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J. Exp. Med. 178 (1993), 1567–1575.
15. [15] Gerritse, K., Laman, J.D., Noelle, R.J., Aruffo, A., Ledbetter, J.A., Boersma, W.J., et al. CD40–CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 2499–2504.
16. [16] Van den Eertwegh, A.J., Noelle, R.J., Roy, M., Shepherd, D.M., Aruffo, A., Ledbetter, J.A., et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T–B cell interactions. J. Exp. Med. 178 (1993), 1555–1565.
17. [17] Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (2011), 1612–1616.
18. [18] Kasran, A., Boon, L., Wortel, C.H., Hogezand, R.A., Schreiber, S., Goldin, E., et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment. Pharmacol. Ther. 22 (2005), 111–122.
19. [19] Khalil, M., Vonderheide, R.H., Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther. 2 (2007), 61–65.
20. [20] Vonderheide, R.H., Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13 (2007), 1083–1088.
21. [21] Winter, G., Griffiths, A.D., Hawkins, R.E., Hoogenboom, H.R., Making antibodies by phage display technology. Annu. Rev. Immunol. 12 (1994), 433–455.
22. [22] Ignatovich, O., Jespers, L., Tomlinson, I.M., de Wildt, R.M., Creation of the large and highly functional synthetic repertoire of human VH and Vkappa domain antibodies. Methods Mol. Biol. 911 (2012), 39–63.
23. [23] McCafferty, J., Griffiths, A.D., Winter, G., Chiswell, D.J., Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 (1990), 552–554.
24. [24] Matsuura, J.E., Morris, A.E., Ketchem, R.R., Braswell, E.H., Klinke, R., Gombotz, W.R., et al. Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule. Arch. Biochem. Biophys. 392 (2001), 208–218.
25. [25] Clark, E.A., Ledbetter, J.A., Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 4494–4498.
26. [26] Adams, A.B., Shirasugi, N., Jones, T.R., Durham, M.M., Strobert, E.A., Cowan, S., et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174 (2005), 542–550.
27. [27] Grochulski, P., Fodje, M.N., Gorin, J., Labiuk, S.L., Berg, R., Beamline 08ID-1, the prime beamline of the Canadian macromolecular crystallography facility. J. Synchrotron Radiat. 18 (2011), 681–684.
28. [28] Kabsch, W., Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66 (2010), 133–144.
29. [29] Kabsch, W., XDS, Acta Crystallographica section D. Biol. Crystallogr. 66 (2010), 125–132.
30. [30] Otwinowski, Z.W., Minor, W., Processing of X-ray Diffraction Data Collected in Oscillation Mode. Carter, Sweet, (eds.) Methods Enzymol, Macromolecular Crystallography Part A, 276, 1997, 307–326.
31. [31] McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
32. [32] Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D: Biol. Crystallogr. 66 (2010), 213–221.
33. [33] Sheriff, S., Some methods for examining the interactions between two molecules. ImmunoMethods 3 (1993), 191–196.
34. [34] Sheriff, S., Hendrickson, W.A., Smith, J.L., Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. J. Mol. Biol. 197 (1987), 273–296.
35. [35] Cowtan, K., Joint CCP4 and ESF-EACBM newsletter on protein crystallography., 31, 1994, 34–38.
36. [36] Collaborative Computational Project. Number 4. Acta Crystallogr. D Biol. Crystallogr. 50 (1994), 760–763.
37. [37] Boon, L., Brok, H.P., Bauer, J., Ortiz-Buijsse, A., Schellekens, M.M., Ramdien-Murli, S., et al. Prevention of experimental autoimmune encephalomyelitis in the common marmoset (Callithrix jacchus) using a chimeric antagonist monoclonal antibody against human CD40 is associated with altered B cell responses. J. Immunol. 167 (2001), 2942–2949.
38. [38] Boon, L., Laman, J.D., Ortiz-Buijsse, A., den Hartog, M.T., Hoffenberg, S., Liu, P., et al. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 174 (2002), 53–65.
39. [39] Imai, A., Suzuki, T., Sugitani, A., Itoh, T., Ueki, S., Aoyagi, T., et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 84 (2007), 1020–1028.
40. [40] Laman, J.D., Claassen, E., Noelle, R.J., Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16 (1996), 59–108.
41. [41] Laman, J.D., BA, t.'t.H.H., Brok, H., Meurs, M., MM, S., Kasran, A., et al. Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12). Eur. J. Immunol. 32 (2002), 2218–2228.
42. [42] Oura, T., Yamashita, K., Suzuki, T., Fukumori, D., Watanabe, M., Hirokata, G., et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am. J. Transplant. 12 (2012), 1740–1754.
43. [43] Bajorath, J., Chalupny, N.J., Marken, J.S., Siadak, A.W., Skonier, J., Gordon, M., et al. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. Biochemistry 34 (1995), 1833–1844.
44. [44] Bajorath, J., Marken, J.S., Chalupny, N.J., Spoon, T.L., Siadak, A.W., Gordon, M., et al. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry 34 (1995), 9884–9892.
45. [45] An, H.J., Kim, Y.J., Song, D.H., Park, B.S., Kim, H.M., Lee, J.D., et al. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J. Biol. Chem. 286 (2011), 11,226–11,235.
46. [46] Malmborg Hager, A.C., Ellmark, P., Borrebaeck, C.A., Furebring, C., Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies. Scand. J. Immunol. 57 (2003), 517–524.
47. [47] Marsters, S.A., Frutkin, A.D., Simpson, N.J., Fendly, B.M., Ashkenazi, A., Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J. Biol. Chem. 267 (1992), 5747–5750.
48. [48] Singh, J., Garber, E., Van Vlijmen, H., Karpusas, M., Hsu, Y.M., Zheng, Z., et al. The role of polar interactions in the molecular recognition of CD40L with its receptor CD40. Protein Sci. Publ. Prot. Soc. 7 (1998), 1124–1135.
49. [49] Ledbetter, J.A., Grosmaire, L.S., Hollenbaugh, D., Aruffo, A., Nadler, S.G., Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency. Circ. Shock. 44 (1994), 67–72.
50. [50] Badell, I.R., Thompson, P.W., Turner, A.P., Russell, M.C., Avila, J.G., Cano, J.A., et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 12 (2012), 126–135.
51. [51] Barr, T.A., Heath, A.W., Functional activity of CD40 antibodies correlates to the position of binding relative to CD154. Immunology 102 (2001), 39–43.
52. [52] Gladue, R.P., Paradis, T., Cole, S.H., Donovan, C., Nelson, R., Alpert, R., et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol. Immunother.: CII 60 (2011), 1009–1017.
53. [53] Challa, A., Pound, J.D., Armitage, R.J., Gordon, J., Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells. Allergy 54 (1999), 576–583.
54. [54] Pound, J.D., Challa, A., Holder, M.J., Armitage, R.J., Dower, S.K., Fanslow, W.C., et al. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells. Int. Immunol. 11 (1999), 11–20.
55. [55] Heath, A.W., Wu, W.W., Howard, M.C., Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur. J. Immunol. 24 (1994), 1828–1834.
56. [56] White, A.L., Chan, H.T., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763.
57. [57] Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034.
58. [58] Richman, L.P., Vonderheide, R.H., Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology, 3, 2014, e28610.
59. [59] White, A.L., Chan, H.T., French, R.R., Willoughby, J., Mockridge, C.I., Roghanian, A., et al. Conformation of the human immunoglobulin g2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27 (2015), 138–148.
60. [60] Ellmark, P., Ottosson, C., Borrebaeck, C.A., Malmborg Hager, A.C., Furebring, C., Modulation of the CD40–CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology 106 (2002), 456–463.
61. [61] Ma, X., Barthelemy, P.A., Rouge, L., Wiesmann, C., Sidhu, S.S., Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J. Mol. Biol. 425 (2013), 2247–2259.
62. [62] Ramamurthy, V., Krystek, S.R. Jr., Bush, A., Wei, A., Emanuel, S.L., Das Gupta, R., et al. Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure 20 (2012), 259–269.
63. [63] Silvian, L.F., Friedman, J.E., Strauch, K., Cachero, T.G., Day, E.S., Qian, F., et al. Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem. Biol. 6 (2011), 636–647.